Knowledge Hub

Small Molecules vs Biologics: Which is Right for Your Drug Development Program?
Small Molecules vs Biologics: Which is Right for Your Drug Development Program?

The pharmaceutical industry develops therapies using a variety of molecular approaches. Two of the most prominent categories are small molecule drugs and biologics, each offering unique advantages depending on the disease target and treatment strategy.

Mar 27, 2026

How to Scale Cryogenic Chemistry from Lab to  Launch
How to Scale Cryogenic Chemistry from Lab to Launch

Cryogenic chemistry plays a critical role in the synthesis of many active pharmaceutical ingredients (APIs). By operating at very low temperatures (typically between -20°C and -90°C), chemists can reduce impurities, improve selectivity, and enhance safety for highly reactive transformations. These advantages make cryogenic reactions a powerful enabler in drug development.

Mar 27, 2026

HPAPIs & the Growing Need for Well-Contained Chemistry
HPAPIs & the Growing Need for Well-Contained Chemistry

Highly potent active pharmaceutical ingredients (HPAPIs) continue to represent one of the fastest-growing segments of the pharmaceutical industry, driven largely by an increasing focus on targeted therapeutics like antibody-drug conjugates (ADCs).

Mar 25, 2026

Ozonolysis: Efficient, Precise, and Scalable Oxidation for Modern API Manufacturing
Ozonolysis: Efficient, Precise, and Scalable Oxidation for Modern API Manufacturing

Oxidation reactions play a central role in chemical synthesis, enabling medicinal chemists to functionalize molecules while controlling reactivity and selectivity. At manufacturing scale, however, oxidation chemistry presents safety and operational challenges that often push teams toward alternative transformations.

Mar 24, 2026

How Integrated Operations Keep Early-Stage Development Programs on Track
How Integrated Operations Keep Early-Stage Development Programs on Track

Early-stage drug development is fast-moving and rarely predictable. As evidence evolves and priorities shift, sponsors need partners that can adapt quickly without compromising quality or timelines. In a recent case study, we illustrated how integrated drug development and manufacturing operations can provide the flexibility required to keep early programs moving forward, even when unexpected challenges arise.

Mar 24, 2026

Thank You for your Interest. Please enter your details.
Thank You for your Interest. Please enter your details.
Thank You for your Interest. Please enter your details.
loader